Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PRKCI_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKCI_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKCI_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRKCI_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKCI_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRKCI_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRKCI_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKCI_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009015023 | Skin | AK | establishment of protein localization to membrane | 45/1910 | 260/18723 | 2.84e-04 | 2.99e-03 | 45 |
GO:190307818 | Skin | AK | positive regulation of protein localization to plasma membrane | 16/1910 | 62/18723 | 3.70e-04 | 3.61e-03 | 16 |
GO:190437720 | Skin | AK | positive regulation of protein localization to cell periphery | 17/1910 | 69/18723 | 4.44e-04 | 4.16e-03 | 17 |
GO:00085936 | Skin | AK | regulation of Notch signaling pathway | 21/1910 | 95/18723 | 4.96e-04 | 4.58e-03 | 21 |
GO:00510909 | Skin | AK | regulation of DNA-binding transcription factor activity | 66/1910 | 440/18723 | 8.99e-04 | 7.40e-03 | 66 |
GO:003286819 | Skin | AK | response to insulin | 43/1910 | 264/18723 | 1.37e-03 | 1.02e-02 | 43 |
GO:00140092 | Skin | AK | glial cell proliferation | 13/1910 | 51/18723 | 1.45e-03 | 1.06e-02 | 13 |
GO:004819319 | Skin | AK | Golgi vesicle transport | 47/1910 | 296/18723 | 1.46e-03 | 1.06e-02 | 47 |
GO:00705557 | Skin | AK | response to interleukin-1 | 26/1910 | 143/18723 | 2.53e-03 | 1.63e-02 | 26 |
GO:004352318 | Skin | AK | regulation of neuron apoptotic process | 35/1910 | 212/18723 | 2.90e-03 | 1.84e-02 | 35 |
GO:00510927 | Skin | AK | positive regulation of NF-kappaB transcription factor activity | 27/1910 | 152/18723 | 2.97e-03 | 1.87e-02 | 27 |
GO:00990727 | Skin | AK | regulation of postsynaptic membrane neurotransmitter receptor levels | 14/1910 | 62/18723 | 3.32e-03 | 2.03e-02 | 14 |
GO:005140220 | Skin | AK | neuron apoptotic process | 39/1910 | 246/18723 | 3.62e-03 | 2.17e-02 | 39 |
GO:00451979 | Skin | AK | establishment or maintenance of epithelial cell apical/basal polarity | 11/1910 | 44/18723 | 3.87e-03 | 2.29e-02 | 11 |
GO:190121517 | Skin | AK | negative regulation of neuron death | 34/1910 | 208/18723 | 3.87e-03 | 2.29e-02 | 34 |
GO:001605010 | Skin | AK | vesicle organization | 45/1910 | 300/18723 | 5.44e-03 | 3.02e-02 | 45 |
GO:00510919 | Skin | AK | positive regulation of DNA-binding transcription factor activity | 40/1910 | 260/18723 | 5.49e-03 | 3.03e-02 | 40 |
GO:00457471 | Skin | AK | positive regulation of Notch signaling pathway | 11/1910 | 47/18723 | 6.62e-03 | 3.50e-02 | 11 |
GO:000690024 | Skin | AK | vesicle budding from membrane | 13/1910 | 61/18723 | 7.64e-03 | 3.88e-02 | 13 |
GO:00109765 | Skin | AK | positive regulation of neuron projection development | 27/1910 | 163/18723 | 7.82e-03 | 3.97e-02 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCI | SNV | Missense_Mutation | | c.1540N>C | p.Ala514Pro | p.A514P | P41743 | protein_coding | tolerated(0.21) | benign(0.437) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
PRKCI | SNV | Missense_Mutation | | c.1745N>G | p.Phe582Cys | p.F582C | P41743 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PRKCI | deletion | Frame_Shift_Del | novel | c.1551delN | p.Gly518AspfsTer12 | p.G518Dfs*12 | P41743 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PRKCI | SNV | Missense_Mutation | novel | c.238G>A | p.Val80Ile | p.V80I | P41743 | protein_coding | tolerated(1) | benign(0.024) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKCI | SNV | Missense_Mutation | novel | c.697G>C | p.Glu233Gln | p.E233Q | P41743 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
PRKCI | SNV | Missense_Mutation | | c.862N>C | p.Glu288Gln | p.E288Q | P41743 | protein_coding | tolerated(0.06) | possibly_damaging(0.837) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.318N>G | p.Phe106Leu | p.F106L | P41743 | protein_coding | tolerated(0.09) | probably_damaging(0.999) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.157N>C | p.Glu53Gln | p.E53Q | P41743 | protein_coding | tolerated(0.11) | possibly_damaging(0.751) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.1376N>T | p.Ser459Phe | p.S459F | P41743 | protein_coding | tolerated(0.06) | possibly_damaging(0.878) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCI | SNV | Missense_Mutation | | c.880G>A | p.Glu294Lys | p.E294K | P41743 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GSK-269962A | GSK-269962A | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | ILORASERTIB | ILORASERTIB | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL608533 | MIDOSTAURIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | SOPHORETIN | QUERCETIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3545332 | CEP-2563 | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 135652717 | STAUROSPORINE | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL574737 | UCN-01 | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SOTRASTAURIN | SOTRASTAURIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL565612 | SOTRASTAURIN | |
5584 | PRKCI | KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | INGENOL MEBUTATE | | |